Incidence and risk factors for major bleeding among patients undergoing percutaneous coronary intervention: Findings from the Norwegian Coronary Stent Trial (NORSTENT)
Open Access
- 4 March 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3), e0247358
- https://doi.org/10.1371/journal.pone.0247358
Abstract
Introduction: Bleeding is a concern after percutaneous coronary intervention (PCI) and subsequent dual antiplatelet therapy (DAPT). We herein report the incidence and risk factors for major bleeding in the Norwegian Coronary Stent Trial (NORSTENT). Materials and methods: NORSTENT was a randomized, double blind, pragmatic trial among patients with acute coronary syndrome or stable coronary disease undergoing PCI during 2008–11. The patients (N = 9,013) were randomized to receive either a drug-eluting stent or a bare-metal stent, and were treated with at least nine months of DAPT. The patients were followed for a median of five years, with Bleeding Academic Research Consortium (BARC) 3–5 major bleeding as one of the safety endpoints. We estimated cumulative incidence of major bleeding by a competing risks model and risk factors through cause-specific Cox models. Results: The 12-month cumulative incidence of major bleeding was 2.3%. Independent risk factors for major bleeding were chronic kidney disease, low bodyweight (< 60 kilograms), diabetes mellitus, and advanced age (> 80 years). A myocardial infarction (MI) or PCI during follow-up increased the risk of major bleeding (HR = 1.67, 95% CI 1-29-2.15). Conclusions: The 12-month cumulative incidence of major bleeding in NORSTENT was higher than reported in previous, explanatory trials. This analysis strengthens the role of chronic kidney disease, advanced age, and low bodyweight as risk factors for major bleeding among patients receiving DAPT after PCI. The presence of diabetes mellitus or recurrent MI among patients is furthermore a signal of increased bleeding risk. Clinical trial registration: Unique identifier NCT00811772; http://www.clinicaltrial.gov.Funding Information
- Helse Nord RHF (HNF1420-18)
This publication has 33 references indexed in Scilit:
- Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort studyJournal of Cardiology, 2016
- Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA, 2016
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsThe New England Journal of Medicine, 2014
- Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet TherapyJournal of Invasive Cardiology, 2014
- Multiple imputation of covariates by fully conditional specification: Accommodating the substantive modelStatistical Methods in Medical Research, 2014
- Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyThe Lancet, 2013
- Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitroBMC Nephrology, 2012
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsJournal of the American College of Cardiology, 2011
- Predictors of Bleeding and Time Dependence of Association of Bleeding With MortalityJournal of the American College of Cardiology, 2011
- Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry dataThe Lancet, 2009